Abstract 1992P
Background
Clinical trials suggest that prior NAC treatment may improve adjuvant NIVO outcomes in pts with MIUC at high risk for recurrence after radical resection; investigation in RW pts could help inform treatment sequencing. We characterized RW pts with MIUC who received adjuvant NIVO stratified by whether they received prior NAC.
Methods
In this retrospective medical chart review of pts with stage II-IIIB MIUC who began adjuvant NIVO between 9/1/2021 and 11/25/2022, physicians from the Cardinal Health Oncology Provider Extended Network abstracted pt data from electronic records. Pt characteristics and survival point estimates per Kaplan–Meier analyses were summarized via descriptive statistics.
Results
253 pts with MIUC were treated with adjuvant NIVO; 141 (55.7%) received and 112 (44.3%) did not receive NAC. Median NAC duration was 2.8 mo; gemcitabine plus cisplatin (84.4%) was the most common regimen. Pts who received NAC were younger at diagnosis (mean, 64.0 vs 70.8 y) and more likely to have commercial insurance (40.4% vs 9.8%) vs pts who did not receive NAC. At adjuvant NIVO initiation, more pts who received NAC had stage IIIB disease (30.5% vs 17.9%), better functional status (ECOG PS 0 or 1, 97.2% vs 63.4%), and fewer comorbidities (mean NCI comorbidity index, 0.33 vs 0.71) vs pts who did not receive NAC. Majority of pts who did not receive NAC were cisplatin ineligible (78.6% vs 6.4%); the most common eligibility criterion was creatinine clearance (88.5%). Median follow-up from start of adjuvant NIVO was 13.3 mo in pts who received NAC and 12.3 mo in pts who did not receive NAC. Pts who received NAC had better 18-mo overall survival (90.1% vs 55.5%, P = 0.02) and 18-mo distant metastasis-free survival (86.6% vs 54.6%, P < 0.01) outcomes from the start of adjuvant NIVO.
Conclusions
Pts with MIUC who received NAC before adjuvant NIVO were overall younger, healthier, and more likely to have stage IIIB disease. RW outcomes of adjuvant NIVO were favorable overall, and NAC pts showed improved outcomes vs pts who did not receive NAC. Further research with extended follow-up and adjustment for baseline characteristics is needed to elucidate observed differences.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Bristol Myers Squibb.
Funding
Bristol Myers Squibb.
Disclosure
W.S. John: Financial Interests, Institutional, Local PI: Bristol Myers Squibb, Sobi, Inc., Pfizer, AbbVie, Bayer, Janssen, Daiichi Sankyo Inc. S. Lucht: Financial Interests, Institutional, Full or part-time Employment: Cardinal Health; Non-Financial Interests, Personal, Other, Covered travel and accommodation expenses to lobby U.S. Congress on behalf of cancer research funding for the NIH in Spring 2023: American Association for Cancer Research; Non-Financial Interests, Member: American Association for Cancer Research. T. Miller: Financial Interests, Institutional, Full or part-time Employment, Former employee from 2021 to Nov 2023: Cardinal Health; Financial Interests, Institutional, Stocks/Shares: Flatiron Health. P. Pathak: Financial Interests, Personal, Other, Contractor: Cardinal Health. E. Bland: Financial Interests, Institutional, Full or part-time Employment: Cardinal Health. A.J. Klink: Financial Interests, Personal, Full or part-time Employment, Employee: Cardinal Health; Financial Interests, Personal, Stocks/Shares, Employee Stock LTI: Cardinal Health; Financial Interests, Institutional, Funding: Astellas, BMS, BI, Bayer, AbbVie, Alexion, Adaptimmune, Ascentage, AstraZeneca, Daiichi, Eisai, EmitBio, Fresenius Kabi, Genentech, Greenwich, GSK, Hookipa, Incyte, Janssen, Jazz, Kite, MorphoSys, Pfizer, Taiho, Teva. B.A. Feinberg: Financial Interests, Institutional, Full or part-time Employment: Cardinal Health. N. Singh: Financial Interests, Personal, Full or part-time Employment, employee: Bristol Myers Squibb; Financial Interests, Personal, Stocks/Shares, carry stocks: Bristol Myers Squibb; Non-Financial Interests, Institutional, Proprietary Information, RWE data: Bristol Myers Squibb. C. Alonso: Financial Interests, Personal, Full or part-time Employment, I am employed by Bristol Myers Squibb: Bristol Myers Squibb; Financial Interests, Personal, Stocks/Shares: Bristol Myers Squibb. M. Patel: Financial Interests, Personal, Full or part-time Employment: Bristol Myers Squibb; Financial Interests, Personal, Stocks/Shares: Bristol Myers Squibb. L.C. Rosenblatt: Financial Interests, Personal, Full or part-time Employment: Bristol Myers Squibb; Financial Interests, Personal, Stocks/Shares: Bristol Myers Squibb. X. Yin: Financial Interests, Personal, Full or part-time Employment: Bristol Myers Squibb. A. Chehrazi-Raffle: Financial Interests, Personal, Advisory Board: Exelixis, Inc, Aveo Inc., Pfizer Inc.; Financial Interests, Personal, Invited Speaker: Exelixis, Inc, OncLive/MJH Life Sciences, ASCO Direct. All other authors have declared no conflicts of interest.
Resources from the same session
1978P - Accurate detection of urothelial carcinoma by whole-genome methylation profiling of urinary cell-free DNA
Presenter: Huiqin Guo
Session: Poster session 13
1979P - Disitamab vedotin (DV) plus toripalimab (T) in unresectable locally advanced or metastatic urothelial carcinoma (la/mUC): Long-term outcomes from a phase Ib/II study
Presenter: Li Zhou
Session: Poster session 13
1980P - Association of PD-L1 expression with clinical response to TAR-200 in the phase IIb SunRISe-1 trial
Presenter: Evanguelos Xylinas
Session: Poster session 13
1981P - Cabozantinib plus durvalumab in patients with advanced and chemotherapy-treated urothelial carcinoma (UC) and variant histology (VH): An open-label, phase II, single-arm proof-of-concept trial: ARCADIA study. Subgroup analysis for bone metastasis
Presenter: Marco Stellato
Session: Poster session 13
1982P - Post hoc analysis of outcomes according to prior chemotherapy (CT) response and platinum agent in the international SAUL study of atezolizumab (atezo) for urinary tract carcinoma (UTC)
Presenter: Begona Perez Valderrama
Session: Poster session 13
1983P - Feasibility and efficacy of split-dose cisplatin with atezolizumab for cisplatin-ineligible urothelial carcinoma (SOGUG-AUREA): Final results
Presenter: Guillermo Antonio De Velasco Oria
Session: Poster session 13
1984P - Efficacy and safety of disitamab vedotin combined with gemcitabine as neoadjuvant therapy for muscle-invasive bladder cancer: A multi-center, single-arm, phase II trial
Presenter: Chu Yang
Session: Poster session 13
1985P - Retrospective database analysis of real-world treatment patterns and sequencing in locally advanced or metastatic urothelial carcinoma patients receiving sacituzumab govitecan
Presenter: Ronac Mamtani
Session: Poster session 13
1986P - Prospective evaluation of BCG unresponsive bladder cancer carcinoma in situ identifies genetic mechanisms of immunotherapy resistance and targeted therapy using an ultra-sensitive next generation sequencing minimal residual disease (MRD) assay
Presenter: Joshua Meeks
Session: Poster session 13